Search Results - "LENEHAN, P. F"

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone by SMALL, E. J, MEYER, M, MARSHALL, M. E, REYNO, L. M, MEYERS, F. J, NATALE, R. B, LENEHAN, P. F, LIANG CHEN, SLICHENMYER, W. J, EISENBERGER, M

“…Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective…”
Get full text

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival by SMALL, Eric J, MCMILLAN, Alex, MEYER, Mark, LIANG CHEN, SLICHENMYER, William J, LENEHAN, Peter F, EISENBERGER, Mario

“…Validated end points are lacking for clinical trials in hormone-refractory prostate cancer (HRPC). Controversy remains regarding the utility of a posttreatment…”
Get full text

Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells by LENEHAN, P. F, GUTIERREZ, P. L, WAGNER, J. L, MILAK, N, FISHER, G. R, ROSS, D. D

“…It has been recognized that enhanced antioxidant defenses can contribute to the resistance of cancer cells displaying multidrug resistance (MDR) that arises in…”
Get full text

External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC) by Lenehan, P. F., Boardman, L. A., Fry, D. W., Heyman, E. R., Ohrnberger, J., Worzel, W. P.

“…Abstract only…”
Get full text

External validation of a tumor-derived 5-gene prognostic signature for recurrence (R) of stages I/II colon and stage I rectal cancer following potentially curative resection by Lenehan, P. F., Boardman, L. A., Fry, D. W., Heyman, E. R., Ohrnberger, J., Worzel, W. P.

“…Abstract only 437 Background: Optimizing post-operative clinical management for early-stage (I/II) colorectal cancer (CRC) patients (pts) is a significant…”
Get full text

Generation and validation of a primary-tumor-derived four-gene prognostic signature for recurrence (R) of stages I/II colorectal cancer (CRC) following potentially curative resection by Lenehan, P. F., Fry, D. W., Heyman, E. R., Eliason, J. F., Worzel, W. P.

“…Abstract only 4035 Background: Current guidance for postoperative clinical management of stages I/II CRC patients (pts) is suboptimal. We hypothesized that a…”
Get full text

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer by CAMPOS, Susana, HAMID, Oday, CHARBONNEAU, Claudie, HIRTE, Hal, SEIDEN, Michael V, OZA, Amit, PLANTE, Marie, POTKUL, Ronald K, LENEHAN, Peter F, KALDJIAN, Eric P, VARTERASIAN, Mary L, JORDAN, Cheryl

“…To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to determine…”
Get full text

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer by Allen, Lee F., Lenehan, Peter F., Eiseman, Irene A., Elliott, William L., Fry, David W.

Get full text

Administration of CI-1033, an irreversible Pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study by CALVO, Emiliano, TOLCHER, Anthony W, ROWINSKY, Eric K, HAMMOND, Lisa A, PATNAIK, Amita, DE BONO, Johan S, EISEMAN, Irene A, OISON, Stephen C, LENEHAN, Peter F, MCCREERY, Heather, LORUSSO, Patricia

“…To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all…”
Get full text

Effects of sera of normal, anemic and leukemic rats on particle size distribution of 99mtechnetium-sulfur colloid in vitro by Dornfest, B S, Lenehan, P F, Reilly, T M, Mestler, G E, Steigman, J, Solomon, N A

Get more information